Literature DB >> 28376205

Association of Uba6-Specific-E2 (USE1) With Lung Tumorigenesis.

Seong-Jin Kim1, Tae Hyeong Lee1, Sang Hee Nam1, Ji-Hong Kim1, Sangho Oh2, Yeon Sook Cho1, Myeong Sup Lee1, Sehoon Choi3, Peter C W Lee1.   

Abstract

Background: The UBA6-specific E2 conjugating enzyme 1 (USE1) ubiquitin enzyme cascade is a poorly characterized arm of the ubiquitin-proteasome system. We investigated whether the UBA6-USE1 enzyme cascade plays a role in lung cancer tumorigenesis.
Methods: USE1 expression was assessed in tumor-normal paired samples from 106 lung cancer patients by immunoblot. USE1 was stably overexpressed and knocked down in lung cancer cell lines to evaluate cell proliferation, colony formation, and invasion. Xenograft models were used to determine the effects of USE1 on tumor growth (n = 7). Proteomics analysis was used to identify proteins interacting with USE1. The USE1 gene was sequenced in lung cancer patients, and missense mutations of USE1 were generated to evaluate its function. All statistical tests were two-sided.
Results: USE1 proteins were frequently overexpressed in lung cancer patients (92.5%) Stable overexpression of USE1 increased cell proliferation ( P = .002), migration ( P < .001), and invasion ( P < .001), whereas knockdown of USE1 reduced cell proliferation ( P < .001), migration ( P = .003), and invasion in lung cancer cells and xenograft models ( P < .001). USE1 was found to have a conserved D-box domain, and the level of the protein was regulated by the anaphase-promoting complex. Several missense mutations in USE1 identified in patients prolong the stability of the protein. Conclusions: USE1 proteins are frequently overexpressed in lung cancer, and missense mutations in USE1 prolong the half-life of the protein, promoting tumor formation. Our findings reveal novel roles for USE1 in lung cancer and the possible use of USE1 as a novel biomarker and therapeutic target for lung cancer treatment.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28376205     DOI: 10.1093/jnci/djw224

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Authors:  J M Vicencio; R Evans; R Green; Z An; J Deng; C Treacy; R Mustapha; J Monypenny; C Costoya; K Lawler; K Ng; K De-Souza; O Coban; V Gomez; J Clancy; S H Chen; A Chalk; F Wong; P Gordon; C Savage; C Gomes; T Pan; G Alfano; L Dolcetti; J N E Chan; F Flores-Borja; P R Barber; G Weitsman; D Sosnowska; E Capone; S Iacobelli; D Hochhauser; J A Hartley; M Parsons; J N Arnold; S Ameer-Beg; S A Quezada; Y Yarden; G Sala; T Ng
Journal:  Cell Death Dis       Date:  2022-03-28       Impact factor: 9.685

Review 2.  UBA6 and Its Bispecific Pathways for Ubiquitin and FAT10.

Authors:  Fengting Wang; Bo Zhao
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

3.  Ubiquitin Activating Enzyme UBA6 Regulates Th1 and Tc1 Cell Differentiation.

Authors:  Ji Yeon Lee; Eun-Koung An; Juyoung Hwang; Jun-O Jin; Peter C W Lee
Journal:  Cells       Date:  2021-12-29       Impact factor: 6.600

4.  Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines.

Authors:  Yang Wang; Huaicheng Tan; Ting Yu; Xiaoxuan Chen; Fangqi Jing; Huashan Shi
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

5.  A large-scale genetic correlation scan between rheumatoid arthritis and human plasma protein.

Authors:  Pan Luo; Shiqiang Cheng; Feng Zhang; Ruoyang Feng; Ke Xu; Wensen Jing; Peng Xu
Journal:  Bone Joint Res       Date:  2022-02       Impact factor: 5.853

6.  Crystal structures reveal catalytic and regulatory mechanisms of the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6.

Authors:  Lingmin Yuan; Fei Gao; Zongyang Lv; Digant Nayak; Anindita Nayak; Priscila Dos Santos Bury; Kristin E Cano; Lijia Jia; Natalia Oleinik; Firdevs Cansu Atilgan; Besim Ogretmen; Katelyn M Williams; Christopher Davies; Farid El Oualid; Elizabeth V Wasmuth; Shaun K Olsen
Journal:  Nat Commun       Date:  2022-08-19       Impact factor: 17.694

7.  The non-canonical ubiquitin activating enzyme UBA6 suppresses epithelial-mesenchymal transition of mammary epithelial cells.

Authors:  Xianpeng Liu; Limin Sun; Demirkan B Gursel; Chonghui Cheng; Sui Huang; Alfred W Rademaker; Seema A Khan; Jun Yin; Hiroaki Kiyokawa
Journal:  Oncotarget       Date:  2017-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.